Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study

Por: Cejalvo MJ, Legarda M, Abella E, Cabezudo E, Encinas C, García-Feria A, Gironella M, Iñigo B, Martín J, Ribas P, Ruíz MÁ, González Y, Vicuña I, Ramírez Á, Fernández P and de la Rubia J

---

Publicada: 1 sep 2020 Ahead of Print: 1 dic 2019

---

---

Filiaciones:
Cejalvo MJ:
 Department of Hematology, University Hospital Doctor Peset, Valencia, Spain

Legarda M:
 Department of Hematology, University Hospital Doctor Peset, Valencia, Spain

Abella E:
 Department of Hematology, Hospital del Mar, Barcelona, Spain

Cabezudo E:
 Department of Hematology, Hospital Sant Joan de Déu, Barcelona, Spain

Encinas C:
 Department of Hematology, Hospital Gregorio Marañón, Madrid, Spain

García-Feria A:
 Department of Hematology, Hospital de Manises, Valencia, Spain

Gironella M:
 Department of Hematology, Hospital Vall d'Hebron, Barcelona, Spain

Iñigo B:
 Department of Hematology, Hospital Clínico San Carlos, Madrid, Spain

Martín J:
 Department of Hematology, Hospital Virgen del Rocío, Sevilla, Spain

Ribas P:
 Department of Hematology, University Hospital Doctor Peset, Valencia, Spain

Ruíz MÁ:
 Department of Hematology, Hospital Francesc Borja, Gandía, Spain

González Y:
 Department of Hematology, Instituto Catalán de Oncología, Girona, Spain

Vicuña I:
 Department of Hematology, Hospital La Princesa, Madrid, Spain

Ramírez Á:
 Department of Hematology, Hospital Central de Asturias, Oviedo, Spain

:
 Department of Hematology, Hospital General, Alicante, Spain

de la Rubia J:
 Department of Hematology, University Hospital Doctor Peset, Valencia, Spain

 Internal Medicine, School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain